Effectiveness of apixaban in warfarin hepatotoxicity: A case report
Ali A Alaklabi, Abdullah M Alotaibi, Abdulmalik S Alotaibi, M Alessa, Hanan Abdulrahman Habeeb.
Abstract
Background: Apixaban is a direct and competitive inhibitor of factor Xa. It has been shown to be effective and safe to Prevent Stroke in Atrial Fibrillation Patients. This study is a case report of warfarin-induced cholestasis that occurred one week after starting warfarin for deep venous thrombosis, in which the cholestasis improved after the offending drug was stopped but worsened after beginning apixaban.
Case Presentation: We presented a case of 79-year-old woman, she was presented to the emergency depart¬ment with a chief complaint of left lower limb swelling of 3 days duration. On physical examination, her left lower limb was swollen, warm, and tender. Venous Doppler ultrasound showed extensive deep venous throm¬bosis and anticoagulation with unfractionated heparin and warfarin 7 mg initiated.
Conclusion: Apixaban should be avoided in patients with warfarin-induced cholestasis.
Key words: Warfarin, apixaban, hepatotoxicity, anticoagulant, thrombosis, case report.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
